How Long Does Chronic Spontaneous Urticaria Last? Remission, Relapse, and What to Expect

TL;DR

• There is no reliable timeline for how long chronic spontaneous urticaria (CSU) will last in one person. Some people improve within a year, while others have active disease for many years.
• A literature review found reported remission estimates varied widely. Its weighted estimates suggested about 17% were in remission by 1 year, 45% by 5 years, and 73% by 20 years. Definitions and patient populations differed substantially between studies.\[3\]
• Remission is different from having no symptoms while treatment is working. A 2025 World Allergy Organization position paper proposed defining CSU clinical remission as no signs or symptoms without CSU medication for at least 6 months.\[4\]
• CSU can return after months or years without symptoms. Studies have documented recurrence in around 20% of patients who had previously reached remission, although relapse rates vary between populations.\[5,6\]
• In mama health's conversations with Italian CSU patients, relapse was often emotionally difficult because patients had begun to trust that the disease was over.\[1\]
• Rather than relying on a predicted end date, it can help to have a plan for treatment review, remission, medication reduction and what to do if symptoms return.

How long does chronic spontaneous urticaria usually last?

Chronic spontaneous urticaria can last from months to many years, and no single duration applies to everyone.

CSU is defined as spontaneous wheals, angioedema or both recurring for more than six weeks. It can be continuous, intermittent or recurrent.\[2\]

Patients are sometimes told that CSU "usually disappears after a few years." There is some truth behind that reassurance: remission is common over the long term. But the available research does not support giving every patient a simple countdown.

A targeted review of CSU remission studies found substantial variation between published estimates. The proportion reaching remission during the first year ranged from 21% to 47% in individual studies. Reported five-year estimates also varied.

When the authors combined available evidence, their weighted cumulative estimates were approximately 17% in remission at 1 year, 45% at 5 years, and 73% at 20 years.\[3\]

These figures should not be interpreted as a forecast for an individual patient. Studies used different definitions of remission, different populations and different follow-up periods. The review itself highlighted this inconsistency.\[3\]

The more accurate message is therefore: CSU often eventually resolves, but nobody can reliably tell one patient exactly when that will happen.

Can chronic spontaneous urticaria last for decades?

Yes. A minority of people experience CSU for many years or even decades.

Long-term disease is well documented. In one large longitudinal chronic urticaria cohort, median time to remission varied substantially according to disease pattern — ranging from approximately 2.1 years in the lowest-activity group to 9.4 years in the highest-activity group.\[5\] Another prospective study found that more than 70% of participants still had chronic urticaria after one year, while 14% remained affected at five years.\[7\]

mama health's patient conversations reflect this wide range. In the detailed Italian CSU conversations where disease duration, remission and relapse came up, some people described months of disease. Others described years or decades of cycles involving flares, quieter periods and treatment changes.\[1\]

For patients at the longer end of this range, hearing repeatedly that CSU should "go away soon" could become discouraging.

A long disease course does not mean that remission is impossible. It means that CSU prognosis is highly individual.

What does remission mean in CSU?

Remission means the disease remains absent without medication, rather than simply being well controlled by treatment.

This distinction is important because the word remission is often used loosely. Someone receiving omalizumab who has no hives may have complete disease control, but it cannot yet be assumed that their CSU has disappeared.

In 2025, the World Allergy Organization Urticaria Committee proposed defining clinical CSU remission as complete absence of urticaria signs and symptoms without pharmacological treatment — including antihistamines, omalizumab, ciclosporin or systemic corticosteroids — for at least six months.\[4\] The authors also emphasised that there had previously been no globally agreed definition.

For patients, it can therefore help to separate three ideas:

• Active CSU: hives, itching or angioedema are still occurring.
• Controlled CSU: treatment is preventing or adequately controlling symptoms.
• Clinical remission: symptoms remain absent after treatment has been withdrawn for a sustained period.

That distinction becomes particularly important when deciding whether medication might eventually be reduced.

Can CSU go away and then come back?

Yes. CSU can recur after months or even years of complete remission.

The 2026 international guideline explicitly recognises that CSU episodes may recur after months or years of full remission.\[2\]

Published recurrence estimates vary. In one registry of 180 patients, CSU recurrence was recorded in 21% after full remission, with the interval before recurrence ranging from one to ten years.\[6\] A separate longitudinal cohort found that around 20% of patients who reached remission later experienced relapse.\[5\]

Those percentages should not be treated as a universal relapse rate — different studies define remission and relapse differently, and patient populations vary. What they do establish is that remission does not guarantee CSU can never return.

What does a CSU relapse feel like for patients?

A CSU relapse can feel more disruptive than the symptoms alone suggest because it interrupts a period in which patients had started to believe the disease was behind them.

This was one of the strongest themes in mama health's detailed conversations with patients about their disease course.\[1\]

Patients described stretches lasting weeks, months or occasionally years with few or no symptoms. Some occurred during effective treatment, especially omalizumab. Others were described as spontaneous periods without symptoms.

When hives returned, they were often described as sudden. For some patients, angioedema returned as well.

The emotional response could be intense because the return of symptoms challenged the expectation that remission meant the disease was permanently over.\[1\] Patients described disappointment, fear that severe disease was returning, uncertainty about whether previous medication would work again, renewed checking for possible triggers, and frustration that they had not been given a relapse plan.

This patient experience is one reason prognosis conversations should include the possibility of recurrence without suggesting that relapse is inevitable.

How long does it take to find out that urticaria is chronic?

CSU becomes chronic by definition after symptoms have continued or recurred for more than six weeks, but patients may wait much longer before receiving a clear explanation of what is happening.

mama health's patient data show how long that process can become. Looking at the Italian patient conversations where a clear time-to-diagnosis interval could be identified, the typical wait was around four months.\[1\] However, the distribution had a long tail: roughly a third of patients had waited more than a year, and around one in eight had waited more than five years.\[1\]

These patterns describe mama health's own patient conversations rather than the Italian CSU population as a whole.

The detailed narratives help explain some of the delay. Early symptoms were sometimes attributed to allergy, food, stress, or psychological causes.\[1\] Patients could therefore spend considerable time living with unpredictable hives before the word chronic was clearly attached to their experience.

By the time prognosis was finally discussed, some felt that they had already been dealing with the condition for years.

Does having CSU for longer mean it is less likely to go away?

Longer disease duration has been associated with persistence or relapse in several studies, but it cannot reliably predict an individual's future.

Research has identified possible features associated with longer or more severe CSU. A review found that factors reported in association with a longer course included older age at onset, severe disease, angioedema, concomitant chronic inducible urticaria, and sensitivity to aspirin or other NSAIDs.\[7\] An Italian multicentre study of 470 patients treated with omalizumab also found that patients who relapsed after treatment withdrawal tended to have had CSU for longer before treatment.\[8\]

However, associations at population level do not allow a clinician to say precisely: "You have had CSU for three years, therefore you have X years left." The prognosis remains uncertain.

More recent research also illustrates the problem. A 2025 study found longer disease duration among people who relapsed after omalizumab withdrawal, but it was not an independent predictor after other factors were considered.\[9\]

Disease duration provides context. It does not provide a countdown.

Are there signs that CSU is going into remission?

There is no validated symptom pattern or blood test that can confirm in advance that CSU is about to enter permanent remission.

A sustained period of complete control is encouraging, but it does not prove the underlying disease has disappeared. The World Allergy Organization position paper found no validated biomarker capable of identifying patients with a high probability of cure or defining biological remission.\[4\]

This is why treatment step-down is sometimes part of determining whether disease activity remains.

For someone whose CSU has been completely controlled for a sustained period, a healthcare professional may eventually discuss reducing treatment. If symptoms remain absent after medication has been withdrawn, that provides stronger evidence of remission than symptom freedom while medication continues.

Current evidence suggests that treatment reduction can reasonably be considered after a sustained period of control, but the precise timing and method should be individualised.\[4\]

What can trigger a CSU flare or relapse?

CSU can worsen without any identifiable reason, although certain factors can aggravate symptoms in some people.

Patients told mama health they commonly associated worsening with stress, heat, physical pressure, particular foods, and NSAIDs such as ibuprofen.\[1\] These reports need some medical context.

Can stress make CSU worse?

Yes. Stress can aggravate CSU in some people, although it is not accurate to say CSU is simply "caused by stress."

The 2026 guideline notes that up to one-third of patients perceive stress as an aggravating factor and recommends discussing its relationship with disease activity.\[2\] This distinction matters for patients who have previously felt dismissed as "just stressed." Stress can influence symptoms without making the condition psychological or imaginary.

Can NSAIDs worsen CSU?

Yes. NSAIDs can exacerbate pre-existing CSU in some patients.

The guideline identifies NSAIDs as the most common medicines associated with this type of aggravation and estimates that they may exacerbate CSU in up to one-quarter of patients.\[2\] Patients should discuss suspected medication-related flares with a healthcare professional rather than stopping medically necessary drugs independently.

Are foods usually responsible for CSU relapse?

True IgE-mediated food allergy is very rarely the underlying cause of CSU.\[2\]

Some patients nevertheless notice individual foods appearing alongside symptom worsening, and non-allergic food-related exacerbations have been reported. This does not mean broad or long-term elimination diets are appropriate for everyone.

In mama health's patient conversations, years of uncertainty sometimes led patients to increasingly restrict their diets despite never identifying a consistent trigger.\[1\] That pattern can create another burden without necessarily explaining the CSU.

What if heat or pressure reliably causes hives?

Consistent hives after heat or pressure may warrant discussion about chronic inducible urticaria, which can exist alongside CSU.

Heat urticaria and delayed pressure urticaria are recognised subtypes of chronic inducible urticaria.\[2\] This is different from saying that heat or pressure "caused" the underlying CSU. Some people can have more than one form of chronic urticaria at the same time.

Do antihistamines stop working if CSU lasts for years?

Patients sometimes feel that an antihistamine becomes less effective over time, but this does not necessarily mean the body has developed permanent tolerance to the medicine.

This perception appeared frequently in mama health's patient conversations.\[1\] Patients described medications that once seemed sufficient but later no longer controlled their hives.

Several explanations are possible. CSU itself fluctuates in activity. A dose that controlled mild disease may no longer be enough during a more active period. Treatment adherence, dosing, other aggravating factors and changes in the underlying disease can also affect perceived response.

The 2026 guideline recommends adjusting treatment according to current disease control rather than assuming treatment needs will remain fixed throughout the course of CSU.\[2\]

Patients who feel that their antihistamine has "stopped working" could therefore discuss whether disease activity has changed and whether the current treatment strategy still matches their level of control.

Does omalizumab put CSU into remission?

Omalizumab can provide complete symptom control, but symptom freedom on omalizumab is not automatically the same as remission.

This distinction appeared clearly in what patients told mama health. Patients who responded well sometimes described omalizumab as life-changing, especially after years of uncontrolled hives, poor sleep or angioedema.\[1\] Some began to think of themselves as being in remission.

Clinically, however, remission is better assessed after treatment is withdrawn and symptoms remain absent.

Relapse after stopping omalizumab is common in research populations. For example, a 2025 real-world study of 176 adults found that 67% experienced relapse within 12 months after omalizumab discontinuation.\[9\] Another multicentre study using an omalizumab optimisation strategy before withdrawal reported a lower one-year relapse rate of 32.8%.\[10\]

Those different results illustrate an important point: the chance of relapse depends partly on which patients were studied and how treatment was withdrawn. Neither figure predicts what will happen to an individual person.

What happens if CSU returns after stopping omalizumab?

The return of CSU after omalizumab withdrawal does not necessarily mean treatment has permanently stopped working.

Current international guidance recognises relapse after discontinuation and notes that omalizumab can be effective again when treatment is restarted.\[2\]

Patients told mama health that relapse after good control felt particularly upsetting.\[1\] That response makes sense — the medical statement "CSU can relapse" sounds very different from the lived experience of going back to hives and angioedema after rebuilding work, sleep and social routines.

A discussion before treatment reduction can therefore cover what symptoms would count as relapse, who to contact, whether treatment could be restarted, and how quickly the treatment plan would be reviewed.

Knowing that relapse is possible does not mean expecting it. It means not being left without a plan if it occurs.

What if omalizumab becomes less effective over time?

A perceived loss of omalizumab effectiveness should prompt reassessment rather than an assumption that no further options remain.

Some patients told mama health that previously good control became less reliable over time.\[1\] This is a patient-reported pattern. It does not establish one biological mechanism of "waning efficacy."

The 2026 guideline recognises that some people have an insufficient response to standard-dose omalizumab. Specialist-led use of higher doses or shorter intervals has been described, although these approaches can be off-label.\[2\]

The European treatment landscape has also expanded. As of August 2026, remibrutinib, an oral BTK inhibitor, is authorised in the EU for adults with CSU inadequately controlled by H1-antihistamines, and dupilumab is authorised in the EU for moderate-to-severe CSU in patients aged 2 years and older whose disease is inadequately controlled with H1-antihistamines and who have not previously received anti-IgE treatment for CSU.

EU authorisation does not guarantee immediate access or reimbursement in every Italian setting. Patients in Italy can ask their specialist which options are currently available through their local centre and which eligibility criteria apply.

Can thyroid antibodies, IgE or other tests predict remission or relapse?

No currently available blood test can reliably tell one person when their CSU will end or whether it will return.

Researchers have studied total IgE, thyroid autoantibodies, basophil activation, inflammatory markers, D-dimer, and several other biomarkers. Some have shown associations with disease severity, treatment response or duration. But the findings are inconsistent.

The World Allergy Organization remission position paper concluded that there is currently no validated biomarker that can identify patients with a high probability of cure.\[4\]

Recent omalizumab-withdrawal research also demonstrates the uncertainty. A 2025 study found that lower baseline disease control, slower initial omalizumab response and previous relapse were independently associated with recurrence, while total IgE and anti-thyroid peroxidase antibodies were not independent predictors.\[9\]

Testing may still be relevant for understanding CSU subtype, associated autoimmune disease or other clinical questions. It should not be presented as a reliable crystal ball for remission.

If CSU is in remission, should treatment be stopped?

Treatment reduction may be considered after sustained complete control, but there is no single withdrawal plan that applies to every patient.

The goal of CSU management is complete disease control while using the minimum treatment required.\[2\] The World Allergy Organization position paper suggests that treatment reduction can reasonably be considered after approximately six months of control, followed by reassessment after stepping down.\[4\]

Exactly what is reduced first depends on the treatment regimen and individual circumstances — someone using only an antihistamine has a different decision from someone using high-dose antihistamines plus omalizumab.

Patients could discuss how long complete control should continue before reducing treatment, which medication would be reduced first, whether the dose or interval would change, what symptoms would lead to reversing the reduction, and when follow-up would occur.

The purpose of step-down is not to prove that someone can live without medication. It is to determine whether the disease still requires the same amount of treatment.

Why does an uncertain cause make long-term CSU harder to live with?

Not knowing why CSU started can make every relapse feel like a new investigation.

This frustration appeared repeatedly in mama health's conversations with patients.\[1\] Years into the condition, some patients were still asking: "What caused this?"

Without a clear answer, they sometimes relied heavily on self-management strategies such as avoiding foods, avoiding heat, changing detergents, restricting travel, reducing activities, or repeatedly searching for new allergies.\[1\]

CSU can involve autoimmune mechanisms in some patients, while the underlying cause remains uncertain in others.\[2\] A focused clinical investigation can be appropriate. But current guidelines do not recommend indiscriminate testing for every possible cause or trigger.

For patients, an important conversation may therefore be: "Are there investigations that are relevant in my case, and would the result actually change what we do?" That can help separate useful testing from an endless search for a single hidden trigger.

What should you ask your doctor about CSU remission and relapse?

The most useful questions focus less on obtaining an exact end date and more on preparing for different possible disease courses. Based on mama health's patient conversations and current evidence, patients could consider asking:

1. How long has my CSU already been active, and does that tell us anything useful about prognosis?
2. Am I currently in remission, or is my CSU controlled because treatment is working?
3. How do you define remission in your practice?
4. How long should I remain completely controlled before we consider reducing treatment?
5. If we reduce my antihistamine or biologic, what is the plan if hives return?
6. What early signs would you want me to record if a relapse starts?
7. Should I use UAS7, UCT or another symptom record between visits?
8. If omalizumab feels less effective, what options could we discuss?
9. Which newer CSU treatments are actually available to me in Italy?
10. Could heat or pressure mean that I also have an inducible form of urticaria?
11. Are NSAIDs likely to aggravate my CSU based on my history?
12. Is there a reason to investigate thyroid autoimmunity or other biomarkers in my case?
13. Would any of those test results actually change my treatment or prognosis?

These questions are conversation prompts rather than instructions to start, stop or change treatment.

What should you expect from CSU over the long term?

The most realistic expectation is variability rather than a fixed timeline.

CSU can resolve. It can also continue for years. It may become completely quiet, return later or fluctuate between periods of high and low activity.

mama health's conversations with patients make clear why a simple message such as "it usually disappears in a few years" can feel inadequate.\[1\] For some patients, that happens. For others, the disease lasts longer than expected. Some reach excellent control on treatment and then worry about what happens when treatment stops. Others experience a relapse just when they had begun to think of themselves as free from CSU.

Published research supports that uncertainty. Remission becomes more common over time, but estimates vary considerably. Recurrence after full remission is documented. And there is still no laboratory test that can accurately predict one patient's endpoint.\[3,4\]

The useful question is therefore not only "When will this end?" It is also "What is our plan while it is active, what will we do when it becomes quiet, and what will happen if it returns?"

That approach does not promise a timeline medicine cannot provide. It gives patients something more practical: a plan for change.

Disclaimer: This content is informational and not medical advice. mama health offers information and support and does not replace a doctor.